Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AxoGen Inc    AXGN

AXOGEN INC

(AXGN)
  Report  
Delayed Quote. Delayed Nasdaq - 06/21 04:00:00 pm
19.61 USD   -0.81%
05/23AXOGEN : to Participate at Upcoming Investor Conferences
AQ
05/08AXOGEN : 1Q Earnings Snapshot
AQ
05/08AXOGEN : Reports 2019 First Quarter Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against AxoGen, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 07:31pm EDT

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on behalf of those who acquired AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities during the period from August 7, 2017 through December 18, 2018 (the “Class Period”). Investors have until March 11, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that AxoGen failed to disclose that: (i) the Company aggressively increased prices to mask lower sales; (ii) the Company’s pricing alienated customers and threatened the Company’s future growth; (iii) the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (iv) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (v) the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; and (vi) the Company’s key operating metrics, such as number of active accounts, were overstated.

Following the publication of a report by Seligman Investments alleging channel stuffing and the overstatement of active accounts, the price of AxoGen shares fell by $6.17, or approximately 22.4%, to close at $21.36 on December 18, 2018.

If you acquired AxoGen securities during the Class Period, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AXOGEN INC
05/23AXOGEN : to Participate at Upcoming Investor Conferences
AQ
05/08AXOGEN : 1Q Earnings Snapshot
AQ
05/08AXOGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
05/08AXOGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
05/08AXOGEN : Reports 2019 First Quarter Financial Results
AQ
05/02AXOGEN, INC. : Change in Directors or Principal Officers, Amendments to Articles..
AQ
05/02Axogen, Inc. Appoints New Members to Board of Directors
GL
04/24AXOGEN : shares slip on expanded Avance nerve graft study
AQ
04/23AXOGEN : Announces Completion of Planned Interim Analysis and One-Time Enrollmen..
AQ
04/22AXOGEN, INC. : Results of Operations and Financial Condition, Other Events, Fina..
AQ
More news
Financials ($)
Sales 2019 112 M
EBIT 2019 -21,5 M
Net income 2019 -29,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 6,86x
Capi. / Sales 2020 5,22x
Capitalization 768 M
Chart AXOGEN INC
Duration : Period :
AxoGen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXOGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 33,8 $
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Karen L. Zaderej Chairman, President & Chief Executive Officer
Mike Donovan Vice President-Operations
Peter J. Mariani Chief Financial Officer
Ivica Ducic Medical Director-Clinical & Translational Sciences
Angelo G. Scopelianos Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AXOGEN INC-4.01%826
THERMO FISHER SCIENTIFIC31.58%106 107
DANAHER CORPORATION39.38%94 446
BOSTON SCIENTIFIC CORPORATION17.97%53 248
INTUITIVE SURGICAL10.04%52 907
ILLUMINA20.55%44 647